1 Oct. 2022. It’s time again for our quarterly look at the Nasdaq Biotechnology Index, an indicator of investor sentiment in science-based businesses. For six weeks after 30 June, NBI rose about 14 percent to close at 4,281 on 15 Aug., but then bounced up and down over the next six weeks to close yesterday (30 Sept.) at 3,768, slightly higher from where it started for the quarter at 3,749.
For the year-to-date, as noted in today’s chart, NBI shows a general decline, losing more than one-fifth of its value since January. While the NBI’s close yesterday at 3,749 is somewhat of a rebound from the low for the year on 13 June at 3,368, the overall trend for the year is a decline from opening on 3 Jan. at 4,729. By comparison, the Nasdaq Composite Index, an indicator of investor sentiment in the overall technology sector, is down about one-third for the year.
Nasdaq computes NBI from share prices of 365 biotech and pharma companies publicly traded on its exchange. The Nasdaq Composite Index is calculated from share prices of 3,762 companies, nearly all stocks traded on the exchange.
More from Science & Enterprise:
- Infographic – US Biotech Investments Stay Strong
- Infographic – Q2 Venture Funds Decline Continues
- Infographic – Biotech Index Continues Decline in Q2
We designed Science & Enterprise for busy readers including investors, researchers, entrepreneurs, and students. Except for a narrow cookies and privacy strip for first-time visitors, we have no pop-ups blocking the entire page, nor distracting animated GIF graphics. If you want to subscribe for daily email alerts, you can do that here, or find the link in the upper left-hand corner of the desktop page. The site is free, with no paywall. But, of course, donations are gratefully accepted.
[wpedon id=”42724″ align=”center”]
* * *
You must be logged in to post a comment.